Boehringer Ingelheim International GmbH - Company Profile

Powered by

All the data and insights you need on Boehringer Ingelheim International GmbH in one report.

  • Save hours of research time and resources with
    our up-to-date Boehringer Ingelheim International GmbH Strategy Report

  • Understand Boehringer Ingelheim International GmbH position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Boehringer Ingelheim International GmbH: Overview

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.

Gain a 360-degree view of Boehringer Ingelheim International GmbH and make more informed decisions for your business Gain a 360-degree view of Boehringer Ingelheim International GmbH and make more informed decisions for your business Find out more
Headquarters Germany

Address Binger Strasse 173, Ingelheim am Rhein, Rheinland-Pfalz, 55216


Telephone 49 6132 770

No of Employees 53,000

Industry Pharmaceuticals and Healthcare

Revenue (2022) $25.4B

   

   

Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Boehringer Ingelheim International GmbH premium industry data and analytics

2,500+

Clinical Trials

Determine Boehringer Ingelheim International GmbH go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

960+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Boehringer Ingelheim International GmbH’s relevant decision makers and contact details.

730+

Catalyst Calendar

Proactively evaluate Boehringer Ingelheim International GmbH’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

370+

Pipeline Drugs

Identify which of Boehringer Ingelheim International GmbH’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

190+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

170+

Marketed Drugs

Understand Boehringer Ingelheim International GmbH’s commercialized product portfolio to stay one step ahead of the market.

50+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Boehringer Ingelheim International GmbH and assess market opportunity for new entrants with patient population 8-year forecasts.

5

Investigators

Review investigator profiles and find information on trial contacts across Boehringer Ingelheim International GmbH, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

3

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Boehringer Ingelheim International GmbH (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Boehringer Ingelheim International GmbH’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Human Pharmaceuticals: Contract Manufacturing Spiriva
Prescription Medicine Inspiolto Respimat
Cardiometabolic Diseases Striverdi Respimat
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Boehringer Ingelheim International GmbH portfolio and identify potential areas for collaboration Understand Boehringer Ingelheim International GmbH portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In January, the company entered into an agreement with Suzhou Ribo Life Sciences Co Ltd to create novel medicines for those suffering from liver problems.
2023 Acquisitions/Mergers/Takeovers In November, the company announced the acquisition of T3 Pharmaceuticals AG.
2023 Contracts/Agreements In November, the company entered into a partnership with IBM to explore innovative candidate antibodies for the advancement of effective therapeutics.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Boehringer Ingelheim International GmbH F. Hoffmann-La Roche Ltd Pfizer Inc AbbVie Inc Novartis AG
Headquarters Germany Switzerland United States of America United States of America Switzerland
City Ingelheim am Rhein Basel New York North Chicago Basel
State/Province Rheinland-Pfalz - New York Illinois -
No. of Employees 53,000 103,605 88,000 50,000 76,057
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Hubertus von Baumbach Chairman Executive Board - -
Paola Casarosa Managing Director - Innovation Unit Senior Management 2023 49
Gagandeep Singh Head - Human Pharma India; Managing Director Senior Management 2023 -
Shashank Deshpande Managing Director - Animal Health Business Senior Management 2023 50
Michael Schmelmer Managing Director - Finance & Group Functions Senior Management - 58
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Boehringer Ingelheim International GmbH key executives to enhance your sales strategy Gain insight into Boehringer Ingelheim International GmbH key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward